Transgenomic, Inc. ( is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is the global leader in cardiac genetic testing with a family of innovative products, including its flagship C-GAAP test, designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.
Omaha, US
Size (employees)
37 (est)
Transgenomic was founded in 1997 and is headquartered in Omaha, US

Transgenomic Office Locations

Transgenomic has offices in Omaha and New Haven
Omaha, US (HQ)
12325 Emmet St
New Haven, US
5 Science Park

Transgenomic Data and Metrics

Transgenomic Financial Metrics

Transgenomic's revenue was reported to be $1.7 m in FY, 2015 which is a 94% decrease from the previous period.
$, USD

Revenue (FY, 2015)

1.7 m

Revenue growth (FY, 2014 - FY, 2015), %


Gross profit (FY, 2015)

(287 k)

Gross profit margin (FY, 2015), %


Net income (FY, 2015)

(33 m)

EBIT (FY, 2015)

(9.2 m)

Market capitalization (12-Jun-2017)

223.8 k

Closing share price (12-Jun-2017)


Cash (31-Dec-2015)

444 k
Transgenomic's current market capitalization is $223.8 k.
$, USDFY, 2013FY, 2014FY, 2015


27.5 m27.1 m1.7 m

Revenue growth, %


Cost of goods sold

15 m17.4 m1.9 m

Gross profit

12.5 m9.7 m(287 k)

Gross profit Margin, %


Operating expense total

28.3 m27 m8.9 m


(15.8 m)(17.3 m)(9.2 m)

EBIT margin, %


Interest expense

(642 k)(665 k)(724 k)

Interest income

(642 k)(665 k)(724 k)

Pre tax profit

(16 m)(13.4 m)(10.1 m)

Income tax expense

(54 k)524 k

Net Income

(16 m)(13.9 m)(33 m)
$, USDFY, 2013FY, 2014FY, 2015


1.6 m1.6 m444 k

Accounts Receivable

5.3 m7.6 m264 k


4 m3 m

Current Assets

11.8 m13.4 m3.3 m


2 m1.5 m259 k


6.9 m6.9 m

Accounts Payable

2.9 m4.9 m3.8 m

Current Liabilities

8.6 m11.1 m17 m

Additional Paid-in Capital

179.5 m189.7 m200.4 m

Retained Earnings

(168.5 m)(183.6 m)(213.4 m)
$, USDFY, 2013FY, 2014FY, 2015

Net Income

(16 m)(13.9 m)(33 m)

Depreciation and Amortization

2.7 m2.2 m489 k

Accounts Receivable

(2.8 m)(8.5 m)133 k


908 k715 k(113 k)

Accounts Payable

801 k2 m(365 k)

Cash From Operating Activities

(2.9 m)(17 k)(12.4 m)

Purchases of PP&E

(605 k)(130 k)(204 k)

Cash From Investing Activities

(1.8 m)

Interest Paid

724 k229 k493 k
$, USDY, 2015


11 k

Transgenomic Market Value History

Transgenomic Online and Social Media Presence

Transgenomic Company Life and Culture

You may also be interested in